Evaluation of Cytomegalovirus Infections in Liver Transplant Recipients Under Universal Prophylaxis: A Single Centre Experience

Basit Öğe Kaydı
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridtoplu, sibel altunışık/0000-0002-2915-4666
dc.authoridKose, Adem/0000-0002-1853-1243
dc.authoridKARAKAS, SERDAR/0000-0001-8314-7806
dc.authoridBAYINDIR, Yasar/0000-0003-3930-774X
dc.authoridOtlu, Baris/0000-0002-6220-0521
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.authorwosidtoplu, sibel altunışık/ABH-5816-2020
dc.authorwosidKose, Adem/AAD-1226-2020
dc.authorwosidKARAKAS, SERDAR/AAB-3219-2021
dc.contributor.authorToplu, Sibel Altunisik
dc.contributor.authorKose, Adem
dc.contributor.authorKarakas, Serdar
dc.contributor.authorBayindir, Yasar
dc.contributor.authorOtlu, Baris
dc.contributor.authorYilmaz, Sezai
dc.date.accessioned2024-08-04T20:50:42Z
dc.date.available2024-08-04T20:50:42Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Cytomegalovirus (CMV) is one of the leading viral agents that can pave the way for serious complications and organ damage in solid organ transplant (SOT) recipients after transplantation. Strategies have been developed to protect at-risk patients from CMV infection following transplantation. Since more than 90% of adults in Turkey were positive for CMV IgG, universal CMV prophylaxis was applied, and the results were evaluated. Objectives: This study aimed to evaluate the results of universal CMV prophylaxis after liver transplantation in the long term. Methods: A total of 1,090 liver transplant patients were evaluated in terms of CMV infection in the Organ Transplantation Institute of Inonu University, Malatya, Turkey, from October 2014 to December 2019. In order to identify the CMV infections, quantitative nucleic acid amplification (QNAT) was used to detect potential CMV DNA. The cut-off value of CMV DNA was determined to be 1000 copies/mL after transplantation. Results: According to the clinical and laboratory assessments, 33 (3%) patients were diagnosed with CMV infection, and 25 (2.3%) patients were evaluated as possibly having CMV syndrome. Also, eight of the 33 patients were assessed as having end-organ CMV disease and 25 as probable CMV syndrome. In the late period following prophylaxis, CMV infection was observed in 10 (0.9%) cases. The infection rate after prophylaxis (0.9%) was lower than the infection rate (2.1%) seen during prophylaxis. Conclusions: Close clinical follow-up with CMV prophylaxis and strict monitoring of CMV DNA by determining a specific cut-off point are important in the follow-up of liver transplant patients.en_US
dc.identifier.doi10.5812/hepatmon.115370
dc.identifier.issn1735-143X
dc.identifier.issn1735-3408
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85115820706en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://doi.org/10.5812/hepatmon.115370
dc.identifier.urihttps://hdl.handle.net/11616/100225
dc.identifier.volume21en_US
dc.identifier.wosWOS:000701001300003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKowsar Publen_US
dc.relation.ispartofHepatitis Monthlyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCytomegalovirus Infectionen_US
dc.subjectCMV Prophylaxisen_US
dc.subjectEnd-Organ CMV diseaseen_US
dc.subjectLiver Transplantationen_US
dc.subjectProbable CMV Syndromeen_US
dc.subjectQuantitative Nucleic Acid Amplification (QNAT)en_US
dc.titleEvaluation of Cytomegalovirus Infections in Liver Transplant Recipients Under Universal Prophylaxis: A Single Centre Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu